Biovie (BIVI) Operating Income (2016 - 2026)
Biovie (BIVI) posted Operating Income of -$5.4 million for Q1 2026, up 14.0% sequentially from -$6.3 million in Q4 2025, and down 80.22% YoY from -$27.2 million in Q1 2025.
Biovie (BIVI) Operating Income (2016 - 2026) Analysis & Trends
Biovie has reported Operating Income for 11 years, with the latest figure at -$5.4 million in Q1 2026.
- Quarterly Operating Income fell 80.22% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.6 million (down 7.3% YoY) and the FY2025 annual result came in at -$18.1 million, up 43.86% from the prior year.
- Operating Income rose to -$5.4 million in Q1 2026 per BIVI's latest filing, from -$6.3 million in the prior quarter.
- Over five years, Operating Income peaked at -$3.0 million in Q1 2025 and troughed at -$13.8 million in Q1 2023.
- A 5-year average of -$7.5 million and a median of -$7.3 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income surged 92.94% in 2022, then slumped 139.61% in 2023.
- Over 5 years, Operating Income stood at -$11.5 million in 2022, then gained by 23.61% to -$8.8 million in 2023, then gained by 16.95% to -$7.3 million in 2024, then rose by 14.13% to -$6.3 million in 2025, then rose by 14.0% to -$5.4 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$5.4 million, -$6.3 million, and -$5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | -5.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.72 Mn |
| Mar 31, 2026 | -5.39 Mn |
| Dec 31, 2025 | -6.26 Mn |
| Sep 30, 2025 | -5.28 Mn |
| Jun 30, 2025 | -3.66 Mn |
| Mar 31, 2025 | -2.99 Mn |
| Dec 31, 2024 | -7.29 Mn |
| Sep 30, 2024 | -4.12 Mn |
| Jun 30, 2024 | -4.79 Mn |
| Mar 31, 2024 | -7.73 Mn |
| Dec 31, 2023 | -8.78 Mn |
| Sep 30, 2023 | -10.88 Mn |
| Jun 30, 2023 | -10.98 Mn |
| Mar 31, 2023 | -13.77 Mn |
| Dec 31, 2022 | -11.49 Mn |
| Sep 30, 2022 | -8.83 Mn |
| Jun 30, 2022 | -9.29 Mn |
| Mar 31, 2022 | -5.75 Mn |
| Dec 31, 2021 | -6.67 Mn |
| Sep 30, 2021 | -5.55 Mn |